TransMedics Group (TMDX)
(Delayed Data from NSDQ)
$168.06 USD
+1.41 (0.85%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $168.81 +0.75 (0.45%) 7:58 PM ET
1-Strong Buy of 5 1
F Value A Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$168.06 USD
+1.41 (0.85%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $168.81 +0.75 (0.45%) 7:58 PM ET
1-Strong Buy of 5 1
F Value A Growth B Momentum C VGM
Zacks News
Will TransMedics (TMDX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
TransMedics (TMDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Maxar (MAXR) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Maxar's (MAXR) fourth-quarter performance is likely to have benefited from growth in the Imagery and Services segment.
TransMedics' OCS Technology Sees Success in Heart Transplant
by Zacks Equity Research
TransMedics (TMDX) successfully completes heart transplants from DCD donors, using its OCS technology.